Share
Export Citation
APA
MLA
Chicago
Harvard
Vancouver
BIBTEX
RIS
Universitas Hasanuddin
Research output:Contribution to journal›Article›peer-review
Favipiravir does not improve viral clearance in mild to moderate COVID-19 – A systematic review and meta-analysis of randomized controlled trials
Bahar M.A.
Heliyon
Q1Published: 2024Citations: 2
Abstract
The use of favipiravir is questionable in the treatment of outpatients with COVID-19 with mild symptoms. Moderate beneficial effects in the case of patients with moderate symptoms and inpatients should be treated with care due to the limitations of the analysed trials.
Access to Document
10.1016/j.heliyon.2024.e29808Other files and links
- Link to publication in Scopus
- Open Access Version Available
Fingerprint
FavipiravirSciences
Coronavirus disease 2019 (COVID-19)Sciences
Meta-analysisSciences
MedicineSciences
2019-20 coronavirus outbreakSciences
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Sciences
Randomized controlled trialSciences
Systematic reviewSciences
Intensive care medicineSciences
MEDLINESciences
Internal medicineSciences
VirologySciences
DiseaseSciences
ChemistrySciences
OutbreakSciences
BiochemistrySciences
Infectious disease (medical specialty)Sciences